Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Vorinostad & Cutaneous T-cell Lymphomas (CTCL), the US FDA granted regular approval to vorinostat on October 6, 2006, for the treatment of Cutaneous T-cell Lymphomas (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies (1, 2, 3, 4).
The EMA has authorized vorinostat as a histone deacetylase inhibitor for the treatment of cutaneous T‑cell lymphoma, in line with the U.S. indication targeting advanced CTC…